ASSESSING THE INFLUENCE OF INCORPORATING SECONDARY CARDIOVASCULAR EVENTS INTO A TYPE 2 DIABETES MELLITUS (T2DM) COST-EFFECTIVENESS MODEL

被引：0
|
作者：
McEwan, P. [1 ]
Evans, L. M. [2 ]
Bergenheim, K. [3 ]
机构：
[1] CRC, Cardiff, S Glam, Wales
[2] Univ Wales Hosp, Cardiff, Vale Glamorga, Wales
[3] AstraZeneca, Molndal, Sweden
来源：
VALUE IN HEALTH | 2010年 / 13卷 / 07期
关键词：
D O I：
10.1016/S1098-3015(11)72108-8
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
引用
收藏
页码：A293 / A293
页数：1
相关论文
共 50 条
  • [1] Assessing the influence of modelling subsequent cardiovascular events into a type 2 diabetes cost-effectiveness model
    McEwan, P. H.
    Evans, M.
    Bergenheim, K.
    DIABETOLOGIA, 2010, 53
  • [2] IMPACT OF PATIENT WEIGHT TRAJECTORY ON COST-EFFECTIVENESS OF TREATMENTS OF TYPE 2 DIABETES MELLITUS (T2DM)
    Schroeder, M.
    Willis, M.
    Johansen, P.
    Girod, I
    Neslusan, C.
    Thompson, G.
    VALUE IN HEALTH, 2013, 16 (07) : A440 - A440
  • [3] THE COST-EFFECTIVENESS OF DAPAGLIFLOZIN IN COMBINATION WITH INSULIN FOR THE TREATMENT OF TYPE 2 DIABETES MELLITUS (T2DM) IN SPAIN
    Sanchez-Covisa, J.
    Capel, M.
    Schmidt, R.
    Charokopou, M.
    Verheggen, B. G.
    VALUE IN HEALTH, 2014, 17 (07) : A350 - A350
  • [4] COST-EFFECTIVENESS OF SAXAGLIPTIN COMPARED TO SITAGLIPTIN FOR THE TREATMENT OF PATIENTS WITH TYPE 2 DIABETES MELLITUS (T2DM)
    Hutchings, A.
    Tolley, K.
    Achana, F.
    Brereton, N. J.
    Lebmeier, M.
    Mesa, O. A.
    VALUE IN HEALTH, 2011, 14 (07) : A478 - A478
  • [5] THE EFFECT OF TREATMENT INTENSIFICATION ASSUMPTIONS ON ESTIMATES OF COST-EFFECTIVENESS IN TYPE 2 DIABETES MELLITUS (T2DM)
    Willis, M.
    Johansen, P.
    Neslusan, C.
    VALUE IN HEALTH, 2015, 18 (03) : A62 - A62
  • [6] THE COST-EFFECTIVENESS OF SAXAGLIPTIN VERSUS SULFONYLUREA (SU) IN THE TREATMENT OF TYPE 2 DIABETES MELLITUS (T2DM) IN GERMANY
    Erhardt, W.
    Bergenheim, K.
    Townsend, R.
    Puelles, Fernandez de Troconiz J.
    McEwan, P.
    VALUE IN HEALTH, 2010, 13 (07) : A291 - A292
  • [7] DEVELOPMENT OF A MODEL TO ASSESS THE COST-EFFECTIVENESS OF THERAPIES FOR PATIENTS WITH TYPE 2 DIABETES MELLITUS (T2DM) FOLLOWING A REFERENCE MODEL FRAMEWORK
    Aguiar-Ibanez, R.
    Palencia, R.
    Kandaswamy, P.
    Flavin, J.
    Gauthier, A.
    Davies, M. J.
    VALUE IN HEALTH, 2014, 17 (07) : A562 - A562
  • [8] THE COST-EFFECTIVENESS OF SAXAGLIPTIN VERSUS NPH INSULIN IN THE TREATMENT OF TYPE 2 DIABETES MELLITUS (T2DM) IN POLAND
    Kolasa, K.
    Niewada, M.
    de Troconiz, J. Puelles Fernandez
    Townsend, R.
    McEwan, P.
    VALUE IN HEALTH, 2010, 13 (07) : A290 - A290
  • [9] THE IMPORTANCE OF HBA1C EVOLUTION IN COST-EFFECTIVENESS MODELING OF TYPE 2 DIABETES MELLITUS (T2DM)
    Willis, M.
    He, J.
    Neslusan, C.
    Johansen, P.
    Worbes-cerezo, M.
    VALUE IN HEALTH, 2012, 15 (07) : A500 - A500
  • [10] THE COST-EFFECTIVENESS OF DAPAGLIFLOZIN (FORXIGA®) VERSUS INSULIN IN THE TREATMENT OF TYPE 2 DIABETES MELLITUS (T2DM) IN ENGLAND AND WALES
    Charokopou, M.
    McEwan, P.
    Lister, S.
    Callan, L.
    Bergenheim, K.
    Tolley, K.
    Roudaut, M.
    VALUE IN HEALTH, 2013, 16 (07) : A441 - A441
12345